Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Navitoclax Plus Ruxolitinib Combo Elicits Responses Indicative of Myelofibrosis Disease Modification

April 12, 2022
By Audrey Sternberg
Article
Conference|American Association for Cancer Research Annual Meeting (AACR)

Bone marrow fibrosis improvement and variant allele frequency reduction observed with navitoclax plus ruxolitinib for patients with previously treated myelofibrosis may suggest disease modification.

The combination of navitoclax plus ruxolitinib (Jakafi) led to an improvement in bone marrow fibrosis (BMF) and reduction in variant allele frequency (VAF) in patients with myelofibrosis (MF) who progressed on or had suboptimal response with prior ruxolitinib monotherapy, according to results of the phase 2 REFINE trial (NCT03222609) that were reported in a poster at the American Association for Cancer Research (AACR) 2022 Annual Meeting.1

Median overall survival (OS) was not reached (NR) in patients who had at least 1 grade improvement in BMF vs those without at 28.5 months (95% CI, 19.6-NR; P <.01). Similarly, median OS was better in those with 20% or greater reduction in VAF vs without (NR vs 28.5 month, respectively; P = .05). No deaths were observed in patients with either BMF improvement or VAF reduction.

“The association of improvements in BMF and VAF with improved overall survival are suggestive of disease modification,” Naveen Pemmaraju, MD, of The University of Texas MD Anderson Cancer Center, and co-authors of this study wrote in their poster. “The navitoclax plus ruxolitinib regimen led to improved outcomes for patients with MF regardless of HMR [high molecular risk] status.”

Despite the ability of ruxolitinib to reduce splenomegaly and constitutional symptoms associated with MF, underlying disease biology typically remains largely unchanged. Roughly half of all patients will discontinue receiving the JAK2 inhibitor after 3 years, with an expectation of poor prognosis following withdrawal of the agent.2,3 Patients with MF who harbor major hydrophilic region (MHR) mutations—such as ASXL1, EZH2, IDH1/2, SRSF2, and U2AF1 Q157—are at increased risk of experiencing leukemic transformation or premature death. Reversed BMF and VAF reduction may be linked with disease modification, but the clinical benefits of these responses have not played out in research.

The multicenter, open-label REFINE study was undertaken to determine if navitoclax with or without rituximab could lead to spleen volume reduction in patients with MF who previously received ruxolitinib monotherapy. The current analysis reports on exploratory outcomes of BMF, VAF, and HMR in patients treated in cohort 1a (n = 34) and how these correlated with efficacy end points. All patients received at least 1 dose of navitoclax starting at 50 mg/day and escalating to 300 mg daily based on tolerability plus ruxolitinib at the patient’s current stable dose. BMF was assessed locally; VAF reduction of the driver gene, either JAK2 or CALR, was assessed centrally by next-generation sequencing in the blood at baseline and 24 weeks.

Of the 32 patients evaluable for BMF, 12 (38%) had at least 1 grade improvement at any time of the study and 4 (13%) experienced a minimum of 2 grade improvements. Additionally, 26 patients were evaluable for driver gene VAF reduction, of whom 19 harbored mutant JAK2 vs 7 with mutant CALR, 6 (23%) had at least a 20% reduction at 24 weeks. Five patients had responses in both BMF and VAF.

Of the patients achieving 35% spleen volume reduction at any time, median OS was not reached in those with improved BMF (n = 9) vs 28.5 months for those without (n = 6; P <.01). Median OS was not reached in either group of patients with (n = 19) or without (n = 14) HRM (P = .45).

In total, 17 patients discontinued navitoclax because of progressive disease (n = 6), adverse effects (n = 5), receipt of transplant (n = 2), death (n = 2), physician decision (n = 1), and degrading quality of life (n = 1). In total, 33 patients had molecular risk information available and 58% were considered to be at HMR. Median follow-up in survivors was 26.2 months (range, 6.7-36.4).

Median patient age was 68 years (range, 42-86), roughly two-thirds (68%) were men, and all participants had an ECOG performance score of either 0 (47%) or 1 (53%). Median duration of prior ruxolitinib exposure was 91 weeks (range, 19-391). The median spleen volume was 1695 cm3 (range, 466-5047). Seventeen patients (52%) had 3 or more mutated genes; 26 patients (79%) presented with mutated JAK2 and 7 (21%) with mutated CALR (type 1, 57% [n = 4]; type 2, 43% [n = 3]). HMR mutations were ASXL1 (68%), SRSF2 (37%), EZH2 (21%), U2AF1 (5%), and IDH1/2 (5%); 42% had mutations in 2 or more HMR genes.

References

  1. Pemmaraju N, Garcia J, Potluri J, et al. Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy. Presented at: American Association for Cancer Research (AACR) 2022 Annual Meeting; April 8-14, 2022; New Orleans, LA. Abstract LB108 / 2.
  2. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053. doi:10.1182/blood-2013-02-485888
  3. Palandri F, Breccia M, Bonifacio M, et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020;126(6):1243-1252. doi:10.1002/cncr.32664
Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content
Advertisement

68Ga-FAPI-46 PET’s SUVpeak was highest in patients with pancreaticobiliary cancer, sarcoma, lung cancer, and esophageal/gastrointestinal cancer.

68Ga-FAPI-46 PET Acts as Biomarker for FAP-Positive Cancers

Tim Cortese
June 28th 2025
Article

68Ga-FAPI-46 PET’s SUVpeak was highest in patients with pancreaticobiliary cancer, sarcoma, lung cancer, and esophageal/gastrointestinal cancer.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

BMS-986279 Shows Feasibility as Non-Invasive fuc-GM1 Assessment in ES-SCLC

Roman Fabbricatore
June 27th 2025
Article

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

225AC-3BP-3940 Is Safe, Shows Activity in Heavily Pretreated Advanced Breast Cancer

Gina Mauro
June 24th 2025
Article

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.


Use of PET-guided radiotherapy may enable the opportunity to incorporate biological information into the planning and delivery of radiation.

PET-Guided Radiotherapy Successfully Manages Lung and Bone Tumors

Russ Conroy
June 23rd 2025
Article

Use of PET-guided radiotherapy may enable the opportunity to incorporate biological information into the planning and delivery of radiation.

Related Content
Advertisement

68Ga-FAPI-46 PET’s SUVpeak was highest in patients with pancreaticobiliary cancer, sarcoma, lung cancer, and esophageal/gastrointestinal cancer.

68Ga-FAPI-46 PET Acts as Biomarker for FAP-Positive Cancers

Tim Cortese
June 28th 2025
Article

68Ga-FAPI-46 PET’s SUVpeak was highest in patients with pancreaticobiliary cancer, sarcoma, lung cancer, and esophageal/gastrointestinal cancer.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

BMS-986279 Shows Feasibility as Non-Invasive fuc-GM1 Assessment in ES-SCLC

Roman Fabbricatore
June 27th 2025
Article

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

225AC-3BP-3940 Is Safe, Shows Activity in Heavily Pretreated Advanced Breast Cancer

Gina Mauro
June 24th 2025
Article

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.


Use of PET-guided radiotherapy may enable the opportunity to incorporate biological information into the planning and delivery of radiation.

PET-Guided Radiotherapy Successfully Manages Lung and Bone Tumors

Russ Conroy
June 23rd 2025
Article

Use of PET-guided radiotherapy may enable the opportunity to incorporate biological information into the planning and delivery of radiation.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.